Effects of oxytocin versus promestriene on genitourinary syndrome: a pilot, prospective, randomized, double-blind study

What Was Tested

The paper reports a study of Oxytocin, published as a randomized controlled trial.

Who Took Part

The study group was 51 women.

PubMed tags the participants as women only.

A total of 51 postmenopausal women with symptoms of GSM were evaluated.

They were randomized into two groups: oxytocin (25 patients) and promestriene (26 patients) and were evaluated before and after 90 days of treatment; the evaluation was based on the domains of the Female Sexual Function Index (FSFI) (lubrication, satisfaction, and pain during sexual intercourse), clinical visual examination, and vaginal wall thickness.

How the Study Was Run

The researchers set it up as a randomized, double-blind and pilot study.

Because people in this Oxytocin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the women and researchers unaware of who received Oxytocin.

It is described as a pilot, a small early test of whether a larger Oxytocin study would be practical.

The timeline in the abstract includes 90 days.

What Was Measured

PubMed files the paper under topics including Atrophy, Estradiol, Menopause, Oxytocin, Pilot Projects, Postmenopause and Syndrome.

The authors tagged it with the keywords Genitourinary Syndrome, Promestriene and Vulvovaginal Atrophy.

What This Means in Plain Language

The paper is a randomized, double-blind and pilot study of Oxytocin in 51 women over 90 days.

Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2022 (Clinics (Sao Paulo, Brazil)), a journal based in United States.

More context: the Oxytocin compound page, all human trials.